Clinical trial NCT02638129: Naltrexone/Bupropion Cardiovascular Outcomes Study
Official title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 4 Study to Assess the Effect of Naltrexone Hydrochloride and Bupropion Hydrochloride Extended Release Combination on the Occurrence of Major Adverse Cardiovascular Events in Overweight and Obese Subjects With Cardiovascular Disease
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Obesity
Cardiovascular Diseases
Keywords: Drug therapy
Lead sponsor: Orexigen Therapeutics, Inc
Sponsor class: INDUSTRY
First posted: 2015-12-22
Enrollment: 67
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate cardiovascular (CV) safety of naltrexone hydrochloride (HCl) and bupropion HCl extended release combination (NB) compared with placebo and rule out excess risk of major adverse cardiovascular events (MACE) when given in combination with standard of care in overweight and obese participants with documented history of CV disease.

Detailed description: The drug being evaluated in this study is naltrexone hydrochloride (HCl) and bupropion HCl extended release combination (NB). NB is being evaluated in this study to rule out excess cardiovascular risk. This study will evaluate the occurrence of major adverse CV events in participants who take NB compared with placebo given in combination with standard of care in overweight and obese participants with documented history of CV disease.

The study will enroll approximately 8800 patients. After a 2-week lead-in period evaluating tolerance to NB (participants were randomly assigned in a 1:1 ratio to 1 week of NB \[1 tablet per day\] followed by 1 week of placebo \[1 tablet per day\] or 1 week of placebo followed by 1 week of NB), participants will be randomly assigned to one of two treatment groups in a 1:1 ratio, which will remain undisclosed to the patient, study site personnel, and investigator/study physician during the study (unless there is an urgent medical need):

* Naltrexone HCl 8 mg/bupropion 90 mg extended release combination tablets
* Placebo (dummy inactive pill) - this is a tablet that looks like the study drug but has no active ingredient

All participants will be asked to take tablet(s) in the AM and PM at the same time each day throughout the study.

This multi-center trial will be conducted in the United States. The overall time to participate in this study is up to 6 years. Participants will make multiple visits to the clinic, and will be contacted by telephone 30 days after last dose of study drug for a follow-up assessment.

Eligibility criteria: Inclusion Criteria:

1. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.

2. Participant signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.

3. Has body mass index (BMI) ≥27.0 kg/m\^2 at Screening. 4. Is male or female and aged ≥18 years at Screening. 5. A female participant of childbearing potential who is sexually active with a nonsterilized male partner agrees to use routinely adequate contraception from signing of informed consent through 12 weeks after the last dose of study medication.

6. Participant meets at least 1 the following categories of cardiovascular (CV) disease (a-c):

1. Documented coronary artery disease (at least 1 of the following 2 criteria must be satisfied):

   1. A documented history of myocardial infarction (MI) occurring greater than 3 months prior to Screening.
   2. History of coronary revascularization with at least 1 of the following:

      1. Coronary artery bypass graft surgery occurring greater than 3 months prior to Screening.
      2. Percutaneous coronary intervention (PCI) occurring greater than 3 months prior to Screening.
2. Documented peripheral arterial disease (at least 1 of the following 3 criteria must be satisfied):

   1. Current intermittent claudication or verified ischemic ulcer(s) together with documented ankle-brachial index ≤0.85.
   2. History of previous vascular intervention for intermittent claudication or resting limb ischemia greater than 3 months prior to Screening (example: amputation for arterial disease, peripheral bypass, or history of angioplasty/stenting).
   3. History of symptomatic carotid artery disease (requiring revascularization with carotid endarterectomy or stenting) greater than 3 months prior to Screening or ≥50% stenosis on at least one carotid artery documented by duplex ultrasonography, magnetic resonance angiography, computed tomographic angiography, or catheter-based contrast angiography.
3. Documented cerebrovascular disease (at least 1 of the following 2 criteria must be satisfied):

   1. A history of transient ischemic attack confirmed by a neurologist greater than 3 months prior to Screening and clinically and neurologically stable at Screening.
   2. A history of ischemic stroke (with a Modified Rankin Scale Score ≤3) greater than 3 months prior to Screening and clinically and neurologically stable at Screening.

Exclusion Criteria:

1. Has received any investigational compound or investigational device within 3 months prior to Screening.
2. Is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (eg, spouse, parent, child, sibling) or may consent under duress.
3. Has had an MI or unstable angina within 3 months of Screening.
4. Has planned bariatric surgery, cardiac surgery, coronary revascularization, or peripheral artery revascularization.
5. Has history of bariatric surgery (eg, Roux-en-Y gastric bypass, duodenal switch, or sleeve gastrectomy).
6. Has had a procedure for weight loss other than bariatric surgery (eg, gastric banding or any other devices that maybe used in obesity treatment) within past 12 months prior to Screening.
7. Has a history of hypersensitivity or allergies to any component of naltrexone hydrochloride (HCl) and bupropion HCl extended release combination (NB) or excipients.
8. Has a history of cancer that has been in remission for \<5 years prior to Screening. A history of basal cell carcinoma or Stage 1 squamous cell carcinoma of the skin is allowed.
9. Is hemodynamically unstable, including severe heart failure (New York Heart Association Class IV) at Screening.
10. Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 2 years prior to Screening.
11. Has been randomized into a previous NB (Contrave) study or has been exposed to commercially available NB (Contrave) for any period of time prior to Screening.
12. Is taking excluded medications within 28 days of Screening.
13. Has uncontrolled hypertension defined by systolic blood pressure (SBP) ≥160 mm Hg and/or ≥100 mm Hg diastolic blood pressure (DBP) on the average of two seated blood pressure measurements after being at rest at least 5 minutes, confirmed on 2 separate days during the Screening Period.
14. Has severe renal impairment defined by estimated glomerular filtration rate (eGFR) \<30 ml/min/1.73 m\^2 based on the Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI) at Screening.
15. Has a clinical history of liver failure.
16. Has a known infection with human immunodeficiency virus that is being treated with ritonavir, lopinavir or efavirenz.
17. Has known acute hepatitis at Screening.
18. Has chronic use of opioids, defined as longer than 3 months prior to Screening.
19. Has a positive drug screen for cocaine, methamphetamine, methadone, opiates, oxycodone, phencyclidine, and propoxyphene at Screening. A positive screen for amphetamines, barbiturates, benzodiazepines, and cannabinoids is exclusionary if abuse or dependence is suspected.
20. Has a history of seizures (including febrile seizures), cranial trauma, or other conditions that predispose the participant to seizures.
21. Has a history of mania, history of or current diagnosis of bipolar disorder or current diagnosis of active psychosis, active bulimia or anorexia nervosa (binge eating disorder is not exclusionary).
22. Is at risk for suicide attempts based on the judgment of the investigator.
23. If female, the participant is pregnant (confirmed by laboratory testing at screening) or lactating or intending to become pregnant from signing the informed consent through 12 weeks after last dose of study medication; or intending to donate ova during such time period.
24. Has a history of severe ischemic stroke (with a Modified Rankin Scale Score ≥4).
25. Has any major illness or condition that, in the investigator's opinion, prohibits the participant from participating in the study or meeting the planned visit schedule.
26. Is unable to understand verbal or written English or any other language, for which a certified translation of the approved informed consent is available.

Additional exclusion criteria to be assessed at Visit3 prior to Randomization:

1. Participant takes \<75% or \>125% of the Lead-in study medication.
2. Participant discontinues study medication treatment or has a known major adverse cardiovascular events (MACE) reported by investigator during the Double-Blind Lead-in Period.

Primary outcomes:
measure: Time From Treatment Period Randomization to the First Confirmed Occurrence of Major Adverse Cardiovascular Events (MACE)
timeFrame: Day 1 to first confirmed occurrence of MACE (up to 6 years)
Secondary outcomes:
measure: Time From Treatment Period Randomization to the First Confirmed Occurrence of Extended Major Adverse Cardiovascular Events (MACE)
timeFrame: Day 1 to first confirmed occurrence of extended MACE (up to 6 years)
measure: Time From Treatment Period Randomization to the Occurrence of All-Cause Death
timeFrame: Day 1 to the occurrence of all-cause death (up to 6 years)
measure: Time From Treatment Period Randomization to the Occurrence of Cardiovascular Death
timeFrame: Day 1 to the occurrence of cardiovascular death (up to 6 years)
Other outcomes:
Locations:
city: Alexander City
country: United States
state: Alabama
city: Auburn
country: United States
state: Alabama
city: Birmingham
country: United States
state: Alabama
city: Huntsville
country: United States
state: Alabama
city: Campe Verde
country: United States
state: Arizona
city: Chandler
country: United States
state: Arizona
city: Cottonwood
country: United States
state: Arizona
city: Fountain Hills
country: United States
state: Arizona
city: Mesa
country: United States
state: Arizona
city: Phoenix
country: United States
state: Arizona
city: Tucson
country: United States
state: Arizona
city: Fayetteville
country: United States
state: Arkansas
city: Jonesboro
country: United States
state: Arkansas
city: Little Rock
country: United States
state: Arkansas
city: Arvin
country: United States
state: California
city: Bakersfield
country: United States
state: California
city: Chino
country: United States
state: California
city: Downey
country: United States
state: California
city: El Cajon
country: United States
state: California
city: Los Alamitos
country: United States
state: California
city: Los Angeles
country: United States
state: California
city: Pamona
country: United States
state: California
city: Sacramento
country: United States
state: California
city: Santa Ana
country: United States
state: California
city: Santa Monica
country: United States
state: California
city: Denver
country: United States
state: Colorado
city: New London
country: United States
state: Connecticut
city: Stamford
country: United States
state: Connecticut
city: Trumbull
country: United States
state: Connecticut
city: Waterbury
country: United States
state: Connecticut
city: Wilmington
country: United States
state: Delaware
city: Boca Raton
country: United States
state: Florida
city: Bradenton
country: United States
state: Florida
city: Brandon
country: United States
state: Florida
city: Brooksville
country: United States
state: Florida
city: Coral Springs
country: United States
state: Florida
city: Cutler Bay
country: United States
state: Florida
city: Daytona Beach
country: United States
state: Florida
city: Hialeah
country: United States
state: Florida
city: Inverness
country: United States
state: Florida
city: Jacksonville Beach
country: United States
state: Florida
city: Lake Worth
country: United States
state: Florida
city: Largo
country: United States
state: Florida
city: Miami Lakes
country: United States
state: Florida
city: Orlando
country: United States
state: Florida
city: Palm Harbor
country: United States
state: Florida
city: Pembroke Pines
country: United States
state: Florida
city: Ponte Vedra Beach
country: United States
state: Florida
city: Sarasota
country: United States
state: Florida
city: Stuart
country: United States
state: Florida
city: Atlanta
country: United States
state: Georgia
city: Duluth
country: United States
state: Georgia
city: Savannah
country: United States
state: Georgia
city: Honolulu
country: United States
state: Hawaii
city: Pocatello
country: United States
state: Idaho
city: Blue Island
country: United States
state: Illinois
city: Chicago
country: United States
state: Illinois
city: Evanston
country: United States
state: Illinois
city: Gurnee
country: United States
state: Illinois
city: Rock Island
country: United States
state: Illinois
city: Evansville
country: United States
state: Indiana
city: Topeka
country: United States
state: Kansas
city: Louisville
country: United States
state: Kentucky
city: Owensboro
country: United States
state: Kentucky
city: Baton Rouge
country: United States
state: Louisiana
city: Bossier City
country: United States
state: Louisiana
city: Lake Charles
country: United States
state: Louisiana
city: Shreveport
country: United States
state: Louisiana
city: Baltimore
country: United States
state: Maryland
city: Catonsville
country: United States
state: Maryland
city: Bay City
country: United States
state: Michigan
city: Saginaw
country: United States
state: Michigan
city: Port Gibson
country: United States
state: Mississippi
city: Hazelwood
country: United States
state: Missouri
city: Great Falls
country: United States
state: Montana
city: Las Vegas
country: United States
state: Nevada
city: Linden
country: United States
state: New Jersey
city: Moorestown
country: United States
state: New Jersey
city: Albuquerque
country: United States
state: New Mexico
city: Endwell
country: United States
state: New York
city: Great Neck
country: United States
state: New York
city: Mineola
country: United States
state: New York
city: New York
country: United States
state: New York
city: Saratoga Springs
country: United States
state: New York
city: Staten Island
country: United States
state: New York
city: Asheville
country: United States
state: North Carolina
city: Cary
country: United States
state: North Carolina
city: Charlotte
country: United States
state: North Carolina
city: Durham
country: United States
state: North Carolina
city: Greenville
country: United States
state: North Carolina
city: Hickory
country: United States
state: North Carolina
city: Morehead City
country: United States
state: North Carolina
city: Raleigh
country: United States
state: North Carolina
city: Rocky Mount
country: United States
state: North Carolina
city: Salisbury
country: United States
state: North Carolina
city: Winston Salem
country: United States
state: North Carolina
city: Canton
country: United States
state: Ohio
city: Cincinnati
country: United States
state: Ohio
city: Cleveland
country: United States
state: Ohio
city: Columbus
country: United States
state: Ohio
city: Perrysburg
country: United States
state: Ohio
city: Sandusky
country: United States
state: Ohio
city: Willoughby
country: United States
state: Ohio
city: Altoona
country: United States
state: Pennsylvania
city: Camp Hill
country: United States
state: Pennsylvania
city: Doylestown
country: United States
state: Pennsylvania
city: Lansdale
country: United States
state: Pennsylvania
city: Pittsburgh
country: United States
state: Pennsylvania
city: Smithfield
country: United States
state: Pennsylvania
city: Yardley
country: United States
state: Pennsylvania
city: Charleston
country: United States
state: South Carolina
city: Moncks Corner
country: United States
state: South Carolina
city: Mount Pleasant
country: United States
state: South Carolina
city: Simpsonville
country: United States
state: South Carolina
city: Bristol
country: United States
state: Tennessee
city: Jackson
country: United States
state: Tennessee
city: Knoxville
country: United States
state: Tennessee
city: Memphis
country: United States
state: Tennessee
city: Arlington
country: United States
state: Texas
city: Dallas
country: United States
state: Texas
city: Houston
country: United States
state: Texas
city: Katy
country: United States
state: Texas
city: Kingwood
country: United States
state: Texas
city: Palestine
country: United States
state: Texas
city: Plano
country: United States
state: Texas
city: San Antonio
country: United States
state: Texas
city: Bountiful
country: United States
state: Utah
city: Murray
country: United States
state: Utah
city: Ogden
country: United States
state: Utah
city: Orem
country: United States
state: Utah
city: South Ogden
country: United States
state: Utah
city: West Jordan
country: United States
state: Utah
city: West
country: United States
state: Utah
city: Richmond
country: United States
state: Virginia
city: Roanoke
country: United States
state: Virginia
city: Virginia Beach
country: United States
state: Virginia
city: Port Orchard
country: United States
state: Washington
city: Charleston
country: United States
state: West Virginia
city: Kenosha
country: United States
state: Wisconsin
Study officials:
affiliation: Takeda
name: Medical Director Clinical Science
role: STUDY_DIRECTOR
References: